Table 1.
Characteristics of study population.
| Subject characteristics | Before therapy | After therapy | P value |
|---|---|---|---|
| Age (years) | 57 ± 11 | – | – |
| Sex | 8F/7M | – | – |
| BMI (kg/m2) | 28.2 ± 5.6 | 28.1 ± 5.5 | NS |
| PCSK9i | 7 evolocumab/8 alirocumab | – | – |
| Statins | 9yes/6no | – | – |
| Ezetimibe | 15yes | – | – |
| LDL-C (mg/dl) | 201.4 ± 53 | 83.1 ± 33 | <0.05 |
| FGP (mg/dl) | 91.6 ± 10 | 91.3 ± 7.9 | NS |
| 2h-PPG (mg/dl) | 118.4 ± 6.8 | 116.5 ± 7.6 | NS |
| HbA1c (%) | 5.6 ± 0.06 | 5.3 ± 0.1 | NS |
| AUC glucose (mg/dl x min) | 17908 ± 2913 | 16837 ± 2768 | NS |
| AUC insulin (mcUI/ml x min) | 12053 ± 7153 | 9865 ± 3917 | NS |
Table 1 summarizes the main clinical features of study population (age, sex BMI), their basal hypolipidemic therapy and changes of LDL-C, FPG, 2h-PPG (2 hour Post Prandial Glucose) and HbA1c after treatment period. NS, Not Significant.